- Crotonoside
-
- $30.00 / 5mg
-
2025-05-19
- CAS:1818-71-9
- Min. Order:
- Purity: 99.51%
- Supply Ability: 10g
- Crotonoside
-
- $0.00 / 20mg
-
2023-02-24
- CAS:1818-71-9
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | 2-HYDROXYADENOSINE Basic information |
| | 2-HYDROXYADENOSINE Chemical Properties |
| storage temp. | -20°C | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | powder | | density | 2.25±0.1 g/cm3(Predicted) | | Melting point | 237-241 °C(Solv: water (7732-18-5)) | | pKa | 8.25±0.40(Predicted) | | color | White to off-white |
| Safety Statements | 24/25 | | WGK Germany | 3 | | HS Code | 29349990 |
| | 2-HYDROXYADENOSINE Usage And Synthesis |
| Description | Crotonoside is a purine analogue that is structurally similar to pyrazole, which also inhibits the polymerase chain reaction in vitro. Crotonoside has been shown to be an inhibitor of the polymerase chain reaction in vitro, but it is unclear if this activity will translate to in vivo models. | | Uses | 2-?Hydroxyadenosine is an isoquinoline alkaloid displaying anticancer activity. | | Definition | ChEBI: Crotonoside is a purine nucleoside. | | in vivo | Crotonoside(intraperitoneal and intravenous injection; 70 mg/kg, 35 mg/kg; once daily) induces a significant antitumor activity and inhibited xenograft tumor progress as compared to treatment with vehicle[1]. | Animal Model: | NOD-SCID mice with MV4-11 cells[1] | | Dosage: | 70 mg/kg, 35 mg/kg | | Administration: | Intraperitoneal and intravenous injection; 70 mg/kg, 35 mg/kg; once daily | | Result: | Produced significant AML tumor inhibition rates of 93.5% at 70 mg/kg. |
| | target | Adenosine Receptor | | IC 50 | FLT3; HDAC3; HDAC6 |
| | 2-HYDROXYADENOSINE Preparation Products And Raw materials |
|